Allogene Therapeutics Inc

For the period ended Jun 30, 2024. Filed Aug 7, 2024.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2024 · Filed Aug 7, 2024

ALLO$0.93-12.1%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Operations and Comprehensive Loss

(In thousands, except share and per share amounts)

	Three Months Ended June 30,		Six Months Ended June 30,
	2024	2023	2024	2023
Collaboration revenue - related party	$—	$22	$22	$52
Operating expenses:
Research and development	50,355	62,038	102,614	142,276
General and administrative	16,087	18,524	33,354	37,408
Impairment of long-lived assets	4,989	—	4,989	—
Total operating expenses	71,431	80,562	140,957	179,684
Loss from operations	(71,431)	(80,540)	(140,935)	(179,632)
Other income (expense), net:
Interest and other income, net	4,988	3,778	10,421	5,837
Other income and expense, net	85	(2,470)	(844)	(5,405)
Total other income (expense), net	5,073	1,308	9,577	432
Net loss	(66,358)	(79,232)	(131,358)	(179,200)
Other comprehensive loss:
Net unrealized gain on available-for-sale investments	147	2,083	175	6,075
Net comprehensive loss	$(66,211)	$(77,149)	$(131,183)	$(173,125)
Net loss per share, basic and diluted	$(0.35)	$(0.54)	$(0.73)	$(1.23)
Weighted-average number of shares used in computing net loss per share, basic and diluted	190,026,638	146,795,826	179,577,500	145,685,993

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.